معرفی
Drew Endy is a Professor of Bioengineering at Stanford University, where he also serves as the Martin Family University Fellow in Undergraduate Education and faculty codirector of degree programs for the Hasso Plattner Institute of Design. He is a Science Fellow and Senior Fellow (courtesy) at the Hoover Institution, leading the Bio-Strategies and Leadership (BSL) initiative. His work spans synthetic biology, biotechnology policy, and open science.
- Stanford University – Department of Bioengineering, School of Engineering
- Hoover Institution – Bio-Strategies and Leadership
- Freeman Spogli Institute for International Studies – Senior Fellow (courtesy)
Endy's research focuses on synthetic biology, biological engineering, and the democratization of biotechnology. He helped launch undergraduate bioengineering majors at MIT and Stanford and co-founded the International Genetically Engineered Machine (iGEM) competition. His work emphasizes open collaboration, ethical innovation, and the societal implications of biotechnology. He is deeply involved in biotechnology policy, serving on advisory boards for the World Health Organization, OECD, and the Defense Science Board.
His recent publications and public engagements explore mirror life risks, biobonds for infrastructure, US biotech competitiveness, and the cultural potential of fungi through the Open Fung initiative. Themes across his work include biological democracy, sustainable manufacturing, and interdisciplinary innovation.
- Recognized by Esquire magazine as one of the 75 most influential people of the 21st century
- Active advisor to US and international policy bodies on biosecurity and innovation
- Advocate for open science and decentralized biomanufacturing
Endy is a dedicated educator and mentor, supporting interdisciplinary collaboration through Stanford’s d.school and laboratory spaces. He leads initiatives that connect artists, engineers, and scientists to prototype ethical and regenerative futures. His lab hosts projects like Open Fung, which explores mycelium-based materials and open-source biotechnology. He has testified before Congress on biotech strategy and US competitiveness, particularly in relation to China’s growing capabilities.
